China SFDA Advises Public Of Heart Risks With Key Diabetes Drug
This article was originally published in PharmAsia News
Executive Summary
China's State FDA issued a warning to the public about heart risks associated with the diabetes drug rosiglitazone for patients 65 years of age and older